SC 13G: Kyverna Therapeutics, Inc.
Ticker: KYTX · Form: SC 13G · Filed: Nov 12, 2024 · CIK: 1994702
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Kyverna Therapeutics, Inc..
Risk Assessment
Risk Level: low
Filing Stats: 2,495 words · 10 min read · ~8 pages · Grade level 8.4 · Accepted 2024-11-12 07:23:31
Key Financial Figures
- $0.00001 — me of Issuer) Common Stock, par value $0.00001 per share (Title of Class of Securiti
Filing Documents
- tm2427940d1_sc13g.htm (SC 13G) — 107KB
- tm2427940d1_ex-1.htm (EX-99.1) — 10KB
- tm2427940d1_ex-2.htm (EX-99.2) — 10KB
- tm2427940d1_ex-3.htm (EX-99.3) — 10KB
- 0001104659-24-116359.txt ( ) — 139KB
(a)
Item 1(a). Name of Issuer: Kyverna Therapeutics, Inc.
(b)
Item 1(b). Address of Issuer’s Principal Executive Offices: 5980 Horton St., STE 550 Emeryville, CA 94608
(a)
Item 2(a). Name of Person Filing: This Statement is being filed by Westlake BioPartners Fund I, L.P. (“Westlake Fund I”), Westlake BioPartners GP I, LLC (“Westlake GP I”), Westlake BioPartners Opportunity Fund I, L.P. (“Westlake Opportunity Fund I”) and Westlake BioPartners Opportunity GP I, LLC (“Westlake Opportunity GP I” and together with Westlake Fund I, Westlake GP I and Westlake Opportunity Fund I, the “Reporting Entities”) and Dr. Beth C. Seidenberg (“Seidenberg”) and Dr. Sean E. Harper (“Harper”) (together, the “Reporting Individuals”). The Reporting Entities and the Reporting Individuals are collectively referred to as the “Reporting Persons.”
(b)
Item 2(b) Address of Principal Business Office, or if None, Residence: The address of the principal business office of each Reporting Person is c/o Westlake BioPartners, LLC, 3075 Townsgate Road, Suite 140, Westlake Village, California 91361.
(c)
Item 2(c). Citizenship: Each of Westlake GP I and Westlake Opportunity GP I is a limited liability company organized under the laws of the State of Delaware. Each of Westlake Fund I and Westlake Opportunity Fund I is a limited partnership organized under the laws of the State of Delaware. Each of the Reporting Individuals is a citizen of the United States of America.
(d)
Item 2(d). Title of Class of Securities: Common Stock, $0.00001 par value per share.
(e)
Item 2(e). CUSIP Number: 501976104 Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a: Not applicable. Item 4. (a) Amount beneficially owned: See Row 9 of the cover page for each Reporting Person.* (b) Percent of class: See Row 11 of the cover page for each Reporting Person.* (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote See Row 5 of the cover page for each Reporting Person.* (ii) Shared power to vote or to direct the vote See Row 6 of the cover page for each Reporting Person.* (iii) Sole power to dispose or to direct the disposition of See Row 7 of the cover page for each Reporting Person.* (iv) Shared power to dispose or to direct the disposition of See Row 8 of the cover page for each Reporting Person.* * Except to the extent of a Reporting Person’s pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record. Item 5. Not applicable. Item 6. Person. Under certain circumstances set forth in the limited partnership agreement of each of Westlake Fund I and Westlake Opportunity Fund I and the limited liability company agreement of each of Westlake GP I and Westlake Opportunity GP I, the general and limited partners or members, as the case may be, of each of such entities may be deemed to have the right to receive dividends from, or the proceeds from, the sale of securities of the Issuer owned by each such entity of which they are a partner or member, as the case may be. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. Not applicable. Item 8. Id